Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer
Miruna Grecea,1 Olga Soritau,2 Daniel Dulf,1,2 Tudor Eliade Ciuleanu,1,2 Mihnea Zdrenghea2,3 1Iuliu Hatieganu University of Medicine and Pharmacy, Department of Oncology, Cluj-Napoca, Romania; 2Oncology Institute ‘Prof. Dr. Ion Chiricuta’, Cluj-Napoca, Romania; 3Iuliu Hatieganu University of Medicin...
Guardado en:
| Autores principales: | , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/c2900d088b2e4e429ffb9a4c5748f9b3 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Miruna Grecea,1 Olga Soritau,2 Daniel Dulf,1,2 Tudor Eliade Ciuleanu,1,2 Mihnea Zdrenghea2,3 1Iuliu Hatieganu University of Medicine and Pharmacy, Department of Oncology, Cluj-Napoca, Romania; 2Oncology Institute ‘Prof. Dr. Ion Chiricuta’, Cluj-Napoca, Romania; 3Iuliu Hatieganu University of Medicine and Pharmacy, Department of Hematology, Cluj-Napoca, RomaniaCorrespondence: Mihnea ZdrengheaIuliu Hatieganu University of Medicine and Pharmacy, Department of Hematology, Republicii 34-36, Cluj-Napoca, 400015, RomaniaTel +40741100480Fax +40264598606Email mzdrenghea@umfcluj.roAbstract: A decade ago, immune checkpoint blockade emerged as a major breakthrough in oncology, proposing a novel approach by which immune brakes could be released to enhance antitumor responses. Despite apparently modest improvement of the median duration of response, a spectacular doubling of long-term responses as compared to the available standard of care was seen, for instance, in metastatic melanoma. It soon became obvious that the percentage of patients responding to these novel approaches is relatively small, and the importance of an accurate prediction of responders became more and more clear. Strong predictive markers would allow for the administration of immune checkpoint blocker therapy to the patients most likely to benefit from it, and sparing the potential non-responders of a treatment which is far from innocuous, being associated with significant side-effects and, not least, an important price tag. A number of potential response predictors have already been investigated and partly validated, but they do not cover the major unmet need encountered in the current clinical setting. Here, we review biomarkers for immune checkpoint blockade efficacy, either clinically validated and currently in use, or which have been proposed as candidates and are currently under investigation.Keywords: immune checkpoint blockade, predictive biomarkers, PD-L1 expression, microbiome |
|---|